Amaury Thiabaud1, Anne Iten2, Carlo Balmelli3, Laurence Senn4, Nicolas Troillet5, Andreas Widmer6, Domenica Flury7, Peter W Schreiber8, Miriam Vázquez9, Lauro Damonti9, Michael Buettcher10, Danielle Vuichard-Gysin11, Christoph Kuhm11, Alexia Cusini12, Thomas Riedel13, Yvonne Nussbaumer-Ochsner14, Roman Gaudenz15, Ulrich Heininger16, Christoph Berger17, Franziska Zucol18, Sara Bernhard-Stirnemann19, Natascia Corti20, Petra Zimmermann21, Anita Uka21, Anita Niederer-Loher22, Céline Gardiol23, Maroussia Roelens1, Olivia Keiser1. 1. Institut de Santé Globale, Faculté de Médecine de l'Université de Genève, Geneva, Switzerland. 2. Service de prévention et contrôle de l'infection, Direction médicale et qualité, HUG, Geneva, Switzerland. 3. Infection Control Programme, EOC Hospitals, Ticino, Switzerland. 4. Service de médecine préventive hospitalière, CHUV, Lausanne, Switzerland. 5. Service of Infectious Diseases, Central Institute, Valais Hospitals, Sion, Switzerland. 6. Department of Infectious Diseases, University Hospital Basel, Switzerland. 7. Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, Switzerland. 8. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Switzerland. 9. Department of Infectious Diseases, Bern University Hospital (Inselspital), Bern, Switzerland. 10. Paediatric Infectious Diseases, Department of Paediatrics, Children's Hospital, Cantonal Hospital Lucerne, Switzerland. 11. Department of Infectious Diseases, Thurgau Cantonal Hospital, Thurgau, Switzerland. 12. Department of Infectious Diseases, Cantonal Hospital Graubuenden, Chur, Switzerland. 13. Department of Paediatrics, Cantonal Hospital Graubuenden, Chur, Switzerland. 14. Klinik für Innere Medizin, Kantonsspital Spitäler Schaffhausen, Switzerland. 15. Innere Medizin und Infektiologie, Kantonsspital Nidwalden, Stans, Switzerland. 16. Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland. 17. Division of Infectious Diseases and Children's Research Centre, University Children's Hospital Zurich, Switzerland. 18. Paediatric Infectious Diseases, Department of Paediatrics, Cantonal Hospital Winterthur, Switzerland. 19. Children's Hospital Aarau, Switzerland. 20. Unit of General Internal Medicine, Hirslanden Clinic, Zurich, Switzerland. 21. Faculty of Science and Medicine, University of Fribourg, Switzerland / Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland. 22. Children's Hospital of Eastern Switzerland, St Gallen, Switzerland. 23. Swiss Federal Office of Public Health, Bern, Switzerland.
Abstract
BACKGROUND: SARS-CoV-2/COVID-19, which emerged in China in late 2019, rapidly spread across the world with several million victims in 213 countries. Switzerland was severely hit by the virus, with 43,000 confirmed cases as of 1 September 2020. AIM: In cooperation with the Federal Office of Public Health, we set up a surveillance database in February 2020 to monitor hospitalised patients with COVID-19, in addition to their mandatory reporting system. METHODS: Patients hospitalised for more than 24 hours with a positive polymerase chain-reaction test, from 20 Swiss hospitals, are included. Data were collected in a customised case report form based on World Health Organisation recommendations and adapted to local needs. Nosocomial infections were defined as infections for which the onset of symptoms was more than 5 days after the patient’s admission date. RESULTS: As of 1 September 2020, 3645 patients were included. Most patients were male (2168, 59.5%), and aged between 50 and 89 years (2778, 76.2%), with a median age of 68 (interquartile range 54–79). Community infections dominated with 3249 (89.0%) reports. Comorbidities were frequently reported, with hypertension (1481, 61.7%), cardiovascular diseases (948, 39.5%) and diabetes (660, 27.5%) being the most frequent in adults; respiratory diseases and asthma (4, 21.1%), haematological and oncological diseases (3, 15.8%) were the most frequent in children. Complications occurred in 2679 (73.4%) episodes, mostly respiratory diseases (2470, 93.2% in adults; 16, 55.2% in children), and renal (681, 25.7%) and cardiac (631, 23.8%) complications for adults. The second and third most frequent complications in children affected the digestive system and the liver (7, 24.1%). A targeted treatment was given in 1299 (35.6%) episodes, mostly with hydroxychloroquine (989, 76.1%). Intensive care units stays were reported in 578 (15.8%) episodes. A total of 527 (14.5%) deaths were registered, all among adults. CONCLUSION: The surveillance system has been successfully initiated and provides a robust set of data for Switzerland by including about 80% (compared with official statistics) of SARS-CoV-2/COVID-19 hospitalised patients, with similar age and comorbidity distributions. It adds detailed information on the epidemiology, risk factors and clinical course of these cases and, therefore, is a valuable addition to the existing mandatory reporting.
BACKGROUND:SARS-CoV-2/COVID-19, which emerged in China in late 2019, rapidly spread across the world with several million victims in 213 countries. Switzerland was severely hit by the virus, with 43,000 confirmed cases as of 1 September 2020. AIM: In cooperation with the Federal Office of Public Health, we set up a surveillance database in February 2020 to monitor hospitalised patients with COVID-19, in addition to their mandatory reporting system. METHODS:Patients hospitalised for more than 24 hours with a positive polymerase chain-reaction test, from 20 Swiss hospitals, are included. Data were collected in a customised case report form based on World Health Organisation recommendations and adapted to local needs. Nosocomial infections were defined as infections for which the onset of symptoms was more than 5 days after the patient’s admission date. RESULTS: As of 1 September 2020, 3645 patients were included. Most patients were male (2168, 59.5%), and aged between 50 and 89 years (2778, 76.2%), with a median age of 68 (interquartile range 54–79). Community infections dominated with 3249 (89.0%) reports. Comorbidities were frequently reported, with hypertension (1481, 61.7%), cardiovascular diseases (948, 39.5%) and diabetes (660, 27.5%) being the most frequent in adults; respiratory diseases and asthma (4, 21.1%), haematological and oncological diseases (3, 15.8%) were the most frequent in children. Complications occurred in 2679 (73.4%) episodes, mostly respiratory diseases (2470, 93.2% in adults; 16, 55.2% in children), and renal (681, 25.7%) and cardiac (631, 23.8%) complications for adults. The second and third most frequent complications in children affected the digestive system and the liver (7, 24.1%). A targeted treatment was given in 1299 (35.6%) episodes, mostly with hydroxychloroquine (989, 76.1%). Intensive care units stays were reported in 578 (15.8%) episodes. A total of 527 (14.5%) deaths were registered, all among adults. CONCLUSION: The surveillance system has been successfully initiated and provides a robust set of data for Switzerland by including about 80% (compared with official statistics) of SARS-CoV-2/COVID-19 hospitalised patients, with similar age and comorbidity distributions. It adds detailed information on the epidemiology, risk factors and clinical course of these cases and, therefore, is a valuable addition to the existing mandatory reporting.
Authors: M Abbas; T Robalo Nunes; A Cori; S Cordey; F Laubscher; S Baggio; T Jombart; A Iten; L Vieux; D Teixeira; M Perez; D Pittet; E Frangos; C E Graf; W Zingg; S Harbarth Journal: J Hosp Infect Date: 2021-08-27 Impact factor: 3.926
Authors: Maddalena Marconato; Irene A Abela; Anthony Hauser; Magdalena Schwarzmüller; Rheliana Katzensteiner; Dominique L Braun; Selina Epp; Annette Audigé; Jacqueline Weber; Peter Rusert; Eméry Schindler; Chloé Pasin; Emily West; Jürg Böni; Verena Kufner; Michael Huber; Maryam Zaheri; Stefan Schmutz; Beat M Frey; Roger D Kouyos; Huldrych F Günthard; Markus G Manz; Alexandra Trkola Journal: J Clin Invest Date: 2022-06-15 Impact factor: 19.456
Authors: Kayode Oshinubi; Sana S Buhamra; Noriah M Al-Kandari; Jules Waku; Mustapha Rachdi; Jacques Demongeot Journal: Healthcare (Basel) Date: 2022-03-04